Pasar al contenido principal

CONTRIBUCION FUNCIONAL DE LOS MICROARNS A LA TRANSFORMACION NEOPLASICA DE LINFOCITOS B

PID2019-107551RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MYC directly transactivates CR2/CD21, the receptor of the Epstein-Barr virus, enhancing the viral infection of Burkitt lymphoma cells

  • Molina Hoyo, Ester
  • García-Gutiérrez, Lucía
  • Junco, Vanessa
  • Perez-Olivares, Mercedes
  • Yébenes, Virginia G. de
  • Blanco, Rosa
  • Quevedo, Laura
  • Acosta, Juan C.
  • Marín, Ana V.
  • Ulgiati, Daniela
  • Merino, Ramón
  • Delgado, M. Dolores
  • Varela, Ignacio
  • Regueiro, José R.
  • Moreno de Alborán, Ignacio
  • Ramiro, Almudena R.
  • León, Javier
MYC is an oncogenic transcription factor dysregulated in about half of total human tumors. While transcriptomic studies reveal more than 1000 genes regulated by MYC, a much smaller fraction of genes is directly transactivated by MYC. Virtually all Burkitt lymphoma (BL) carry chromosomal translocations involving MYC oncogene. Most endemic BL and a fraction of sporadic BL are associated with Epstein–Barr virus (EBV) infection. The currently accepted mechanism is that EBV is the BL-causing agent inducing MYC translocation. Herein we show that the EBV receptor, CR2 (also called CD21), is a direct MYC target gene. This is based on several pieces of evidence: MYC induces CR2 expression in both proliferating and arrested cells and in the absence of protein synthesis, binds the CR2 promoter and transactivates CR2 in an E-box-dependent manner. Moreover, using mice with conditional MYC ablation we show that MYC induces CR2 in primary B cells. Importantly, modulation of MYC levels directly correlates with EBV’s ability of infection in BL cells. Altogether, in contrast to the widely accepted hypothesis for the correlation between EBV and BL, we propose an alternative hypothesis in which MYC dysregulation could be the first event leading to the subsequent EBV infection., The work was supported by grants PID2020-115903GB-100 to JL and MDD, RTI2018-095673-B-I00 to JRR, PID2019-107551RB-I00 to VG-Y, PID2020-119567RB-I00 to RM, PID2020-117539GB-I00 to IV and PID2019-106773RB-I00 to ARR, all funded by MCIN/AEI/10.13039/501100011033/, Spanish Government, and by “FEDER, Una manera de hacer Europa”, European Union, and by La Caixa HR17-0244 grant to AR. LQ and VJ were recipients of F.P.U. program and Universidad de Cantabria fellowships, respectively. LG-G was a fellow of the Maria Zambrano program, Spanish Government.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL

  • Álvarez-Corrales, Emigdio
  • Moreno-Palomares, Rocío
  • Gómez-Escolar, Carmen
  • Martínez, Mario
  • Moral-Pérez, Udane
  • Laguna-Herrero, María
  • Fuertes, Teresa
  • Estrada, Belén S.
  • Mur, Sonia
  • Bonis, Adriana de
  • Leiva, Magdalena
  • Martínez-Martín, Nuria
  • Somoza, Álvaro
  • Ramiro, Almudena R.
  • Yébenes, Virginia G. de
The RNA-seq datasets generated during the current study are available in the ArrayExpress Functional Genomics Data repository (accession number: E-MTAB-16241)., Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma. Although many patients respond well to R-CHOP immunochemotherapy, those with the activated B-cell (ABC) subtype are often refractory or relapse. Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have improved outcomes, but acquired resistance limits their long-term efficacy. Here, we modeled the development of ibrutinib resistance in ABC-DLBCL and investigated whether the BCR-signaling regulator microRNA-28 (miR-28) can block this process. Using flow cytometry-based competition assays, multicolor clonal barcoding, transcriptomic profiling, and xenograft models, we found that miR-28 expression impairs the emergence of ibrutinib-resistant ABC-DLBCL cells. Mechanistically, miR-28 interferes with the clonal selection process triggered by ibrutinib treatment and rewires transcriptional programs by downregulating mitochondrial and mTOR signaling pathways critical for resistance development. Furthermore, the miR-28-repressed gene signature associated with ibrutinib resistance correlates with improved survival in ibrutinib-treated patients from the PHOENIX trial cohort with the MCD genetic subtype, which is associated with ABC-DLBCL. Finally, the targeted therapeutic delivery of miR-28 via aptamer-guided nanoparticles suppresses ibrutinib-resistant tumor growth in vivo. These findings identify miR-28 as an effective inhibitor of ibrutinib resistance, underscoring its translational potential as an adjunct strategy in ABC-DLBCL therapy., We thank Janssen and the European Genome-phenome Archive for providing access to data from the PHOENIX trial, the members of the B cell biology lab, Balbino Alarcón, José Luis Marina, and María Jesús García de Yébenes for helpful discussions, and Arantzazu Alfranca for providing the LeGO vectors. E.A.C. and R.M.P were supported by PhD fellowships from the Comunidad de Madrid (PIPF-2022/SAL-GL-24469 and PIPF-2023/SAL-GL-29484 respectively), A.R.R. by CNIC funding and V.G.Y. by the Universidad Complutense de Madrid. B.S.E. is supported by a FPI contract from the Spanish Ministry of Science (PRE2022-102696). This work was funded by Spanish Ministerio de Ciencia e Innovación grants PID2019-107551RB-I00/AEI/10.13039/501100011033 and PID2022-137014OB-I00/AEI/10.13039/501100011033/ FEDER, UE to V.G.Y and PID2023-146982OB-I00, CEX2020-001039-S and PID2024-159895OB-100 to A.S, IMDEA Nanociencia and M.L, respectively. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). N.M.M. lab is supported by the grants CNS2022-135636, PID2021-126298OB-I00, PID2024-162320OB-I00 (founded by MCIU/AEI/10.13039/501100011033/FEDER, UE) and HR22-00447 (founded by La Caixa)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001039-S), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001041-S), Peer reviewed